Smither John W — SEC insider filings

SEC reporting owner CIK 1559583. 32 insider filings on record with FilingPulse; latest filed 2026-09-09.

Transaction summary — filings shown

Covers all 32 filings on record, filed 2020-10-01 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Arcutis Biotherapeutics, Inc. (ARQT)Chief Financial Officer10—13 legs · 19,023 sh · $619,52521
GENELUX Corp (GNLX)Director81 leg · 6,250 sh2 legs · 12,900 sh · $53,60010
NewAmsterdam Pharma Co N.V. (NAMS)Director4—1 leg · 1,600 sh · $40,5125
eFFECTOR Therapeutics, Inc. (EFTR)Director5——7
Applied Molecular Transport Inc. (AMTI)Director4——6
MBX Biosciences, Inc. (MBX)Chief Financial Officer1——2

Insider filings — Smither John W

FiledFormIssuerReported transactionsSource
2026-09-094NewAmsterdam Pharma Co N.V. (NAMS)Sale (S): 1,600 @ $25.32EDGAR
2026-08-044MBX Biosciences, Inc. (MBX)Grant/award (A): 28,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0EDGAR
2026-07-024GENELUX Corp (GNLX)Sale (S): 12,000 @ $2.91EDGAR
2026-06-184GENELUX Corp (GNLX)Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0EDGAR
2026-01-094NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0EDGAR
2025-08-294GENELUX Corp (GNLX)Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0EDGAR
2025-01-084NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0EDGAR
2024-12-314/AGENELUX Corp (GNLX)Grant/award (A): 50,469 (derivative) @ $0EDGAR
2024-08-054GENELUX Corp (GNLX)Grant/award (A): 39,541 @ $0 · Grant/award (A): 50,469 (derivative) @ $0EDGAR
2024-06-074GENELUX Corp (GNLX)Purchase (P): 6,250 · Purchase (P): 6,250 (derivative)EDGAR
2024-02-154Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 2,793 · Grant/award (A): 8,572 · Disposition to issuer (D): 8,379 (derivative) · Disposition to issuer (D): 25,718 (derivative)EDGAR
2024-01-034NewAmsterdam Pharma Co N.V. (NAMS)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2023-12-284Applied Molecular Transport Inc. (AMTI)Disposition to issuer (D): 60,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0EDGAR
2023-09-144GENELUX Corp (GNLX)Sale (S): 900 @ $20.78EDGAR
2023-09-134GENELUX Corp (GNLX)Grant/award (A): 6,920 @ $0 · Grant/award (A): 8,447 (derivative) @ $0EDGAR
2023-09-054Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 125,000 (derivative) @ $0EDGAR
2023-06-224eFFECTOR Therapeutics, Inc. (EFTR)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2023-06-154Applied Molecular Transport Inc. (AMTI)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2023-01-244eFFECTOR Therapeutics, Inc. (EFTR)Grant/award (A): 36,875 (derivative) @ $0EDGAR
2022-06-134eFFECTOR Therapeutics, Inc. (EFTR)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-05-264Applied Molecular Transport Inc. (AMTI)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-01-314Applied Molecular Transport Inc. (AMTI)Grant/award (A): 60,000 (derivative) @ $0EDGAR
2021-10-084eFFECTOR Therapeutics, Inc. (EFTR)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2021-08-274eFFECTOR Therapeutics, Inc. (EFTR)Grant/award (A): 24,142 · Grant/award (A): 24,142 (derivative) @ $0 · Grant/award (A): 3,556 (derivative) @ $0EDGAR
2021-03-114Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $32.90 · Sale (S): 1,250 @ $32.90 · Option exercise (M): 500 (derivative) @ $0EDGAR
2021-03-054Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 9,500 @ $0 · Option exercise (M): 12,396 @ $1.68 · Grant/award (A): 28,800 (derivative) @ $0 · Option exercise (M): 12,396 (derivative) @ $0EDGAR
2021-03-034Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 773 @ $34.20EDGAR
2021-02-124Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 750 @ $1.68 · Sale (S): 750 @ $35.64 · Sale (S): 2,000 @ $35.64 · Option exercise (M): 750 (derivative) @ $0EDGAR
2021-02-034Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 1,250 @ $1.68 · Sale (S): 1,250 @ $35 · Sale (S): 3,750 @ $35 · Option exercise (M): 1,250 (derivative) @ $0EDGAR
2021-01-214Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $30 · Sale (S): 1,250 @ $30 · Option exercise (M): 500 (derivative) @ $0EDGAR
2020-12-164Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 1,500 @ $1.68 · Sale (S): 1,500 @ $30 · Sale (S): 3,750 @ $30 · Option exercise (M): 1,500 (derivative) @ $0EDGAR
2020-10-014Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $30 · Sale (S): 1,250 @ $30 · Option exercise (M): 500 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1559583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs